# CABASTY (NCT02961257)

> Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

No report yet. It can be ordered.

- Drugs tested: cabazitaxel
- Indication: docetaxel-treated metastatic castration-resistant prostate cancer in older men

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02961257
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Conditions: Prostate Cancer Metastatic
- Interventions: cabazitaxel; Prednisone; Granulocyte colony-stimulating factor (G-CSF)
- Enrollment: 196
- Primary outcome: Number of grade ≥ 3 neutropenia and/or neutropenic complications

## Indexed commentary on CABASTY so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cabasty-nct02961257